Physician profile
Caitlyn Krusinsky
NPI 1376388041
$2,599.12
in general payments reported to CMS, 2019-2025
27 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $803 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.13 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $352.51 | 2024-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $328.96 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $308.33 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $240.12 | 2024-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $193.17 | 2024-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $145.31 | 2025 | Fanapt |
| Almatica Pharma LLC | $131.81 | 2024-2025 | Loreev Xr |
| Lundbeck LLC | $108.72 | 2024-2025 | Rexulti |
| Harmony Biosciences LLC | $99.99 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.59 | 2024-2025 | Caplyta |
| Alkermes, INC. | $67.00 | 2024-2025 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $64.39 | 2024-2025 | Xelstrym, Secuado |
| Soleno Therapeutics, INC. | $61.50 | 2025 | Vykat Xr |
| Corcept Therapeutics | $54.44 | 2024 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $53.14 | 2024-2025 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $50.91 | 2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $39.37 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $37.87 | 2025 | Lumryz |
| Tris Pharma INC | $37.86 | 2025 | Dyanavel Xr |
| Sequel Med Tech, LLC | $23.87 | 2025 | Twiist |
| E.R. Squibb & Sons, L.L.C. | $22.16 | 2025 | Cobenfy |
| Tandem Diabetes Care, INC. | $19.62 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Bioxcel Therapeutics, INC. | $19.47 | 2024 | Igalmi |
| Corium, LLC | $17.06 | 2024 | Azstarys |
| Vertical Pharmaceuticals, LLC | $15.16 | 2025 | Relexxii |
| Biogen, INC. | $14.91 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $14.88 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlyn Krusinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.